Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses a hair loss treatment formulation containing cyclosporin, minoxidil, and tacrolimus, and mentions ongoing research on hair color reversal. The treatment showed high efficacy in restoring hair color in trials with 40 to 50 people.

The conversation discusses a patent filed by Shiseido for cloning Dermal Papilla (DP) cells to treat hair loss. The method involves using viral vectors to maintain the cells' growth-inducing properties, differing from Replicel's approach with Dermal Sheath Cup (DSC) cells.

First patient dosed with Pyrilutamide (Kintor) Phase III for hair loss treatment. Pyrilutamide differs from approved treatments as it competes with DHT to bind hair follicles, potentially reducing side effects.

The user had a hair transplant with 2000 grafts in the frontal and mid-scalp areas and has been using finasteride and minoxidil for 3 months. The crown area is expected to improve with continued treatment, and results are generally positive so far.

Kintor's KX826 (pyrilutamide) is ineffective at 0.5% and overpriced at 1%, leading to user frustration and calls for fair pricing. Users suggest sticking with proven treatments like Minoxidil and Finasteride.

The user added P5P (vitamin B6) to their shampoo to reduce scalp itch, which improved significantly. They have been using finasteride for hair loss but are exploring additional treatments like topical antiandrogens and prolactin inhibitors.

PP405 is seen as promising but uncertain, with users advised to continue using existing treatments like minoxidil and finasteride. Concerns include its cost, availability, and interaction with hair transplants, while some hope it could complement current treatments.

Pp405 is discussed as a potential hair loss treatment, with humorous suggestions about rectal administration for increased effectiveness. Users joke about unconventional methods and express willingness to try anything for hair regrowth.

PP405 is a new drug in Phase 2 trials for hair loss, generating cautious optimism among users. Some users are currently using finasteride and experiencing side effects, while others are skeptical about unapproved products being sold.

A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.

OP noticed fuller and thicker hair after almost 4 months of using GHK-Cu, a copper-binding peptide, through subcutaneous injections. Some users were skeptical, questioning the authenticity and potential commercial intent behind the post.

PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.

A user's progress in treating their hair loss with finasteride, minoxidil and oral minoxidil, as well as microneedling. Replies to the post have encouraged the user that they are seeing regrowth from the treatments.

PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.

KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.

Verteporfin and FAK inhibitors being looked at as potential treatments for hair regeneration, with updates on the unofficial off-label human trial being discussed.

The conversation discusses using cyproterone acetate at 12.5 mg to manage hair loss, with concerns about its effects on testosterone and potential health issues. Other treatments mentioned include finasteride, dutasteride, minoxidil, and RU58841, with varying experiences and outcomes.

The conversation discusses skepticism and diminishing excitement around the hair loss treatment PP405 due to unclear trial results. It also mentions other treatments like finasteride, minoxidil, VDPHL01 (extended-release minoxidil), and GT20026 as potential options for hair loss management.

Carpronium chloride 5% is a hair growth treatment in Japan, considered less effective than minoxidil or finasteride. Some users report moderate success with it, but its efficacy is not well-verified.

PP405 is a potential hair loss treatment that may reactivate dormant hair follicles, with Phase 3 trials expected. Some users are cautious, suggesting using finasteride in the meantime, while others are skeptical about PP405's effectiveness.

The user has been using finasteride, minoxidil, and a derma stamp for 3 months with significant improvement. They are now adding ketoconazole to their routine.

A 31-year-old male shared his 4.5-month progress using finasteride, topical minoxidil, and dutasteride mesotherapy for hair loss, showing significant improvement in crown density and overall hair texture. He reported no side effects and plans to continue the treatment to assess further results.

GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.

The user's progress with treating their hair loss with finasteride and minoxidil, as well as using a derma-roller infrequently and Nizoral shampoo twice a week. They discussed how helpful it was for the user to post comparison pictures with the same angle and lighting in each.

PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.

A 23-year-old shares progress in hair quality after 4 months using dutasteride, topical minoxidil, and other treatments, noting improved crown thickness but persistent temple thinning. They switched from finasteride to dutasteride due to side effects and started testosterone replacement therapy, which they believe helps mitigate side effects.

A 47-year-old man shared his 4-month hair regrowth progress using Finasteride, Minoxidil, and Ketoconazole shampoo. He adjusted dosages over time and switched to topical Minoxidil with Tretinoin in the fourth month.

PP405 might take 3-4 years to be available, but some claim Everychem offers a similar product, though its effectiveness is debated. Users discuss the risks of using untested grey market products and the potential for adverse effects.

The conversation discusses using topical Calcipotriol and Valproic Acid for hair loss, focusing on their mechanisms involving the VDR receptor and Wnt/beta-catenin pathway. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.